Systems and methods of treating meibomian and sebaceous gland dysfunction. The methods include reducing oxygen concentration in the environment of one or more dysfunctional meibomian and sebaceous glands, thereby restoring a hypoxic status of one or more dysfunctional meibomian and sebaceous glands. The reducing of the oxygen concentration is accomplished by restricting blood flow to the one or more dysfunctional meibomian and sebaceous glands and the environment of one or more dysfunctional meibomian sebaceous glands. The restricting of the blood flow is accomplished by contracting or closing one or more blood vessels around the one or more dysfunctional meibomian or sebaceous glands. The methods also include giving local or systemic drugs that lead to the generation of hypoxia-inducible factors in one or more dysfunctional meibomian and sebaceous glands.

Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.

Described herein is a generalized injection device for delivering formulations of various mechanical properties to precise locations. Of particular interest is the manifestation intended for the application of a thermally responsive hydrogel to the tear duct for the purpose of occlusion, as a treatment for symptoms associated with dry eye syndrome. Further, a modular solution to the need for an injection device across a variety of applications, mechanism, and physical considerations is provided. This disclosure provides examples of methods for precise injection of low volumes, moisture retention in pre-filled injection devices, and actuation for automatic or manual injection, to name a few.

Disclosed herein are drug delivery punctal implants and methods of using the implants for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The physical arrangement of drugs within the punctal plugs disclosed herein results, in several embodiments, in advantageous controlled delivery of one or more drugs to the eye of a patient.

A punctum plug or lacrimal insert is constructed of a monolithic material, such that the punctum plug is configured to turn approximately 90 degrees upon insertion into a canaliculus of an eye. The punctum plug or lacrimal insert may include high-molecular-weight polysaccharide and added plasticizers.

Devices and methods for inserting a pre-loaded intracanalicular plug for the treatment of dry eyes. In one embodiment, an intracanalicular plug inserter device includes: (a) an elongate body having a longitudinal axis, the body having: an inserter end, wherein the inserter end has an opening therein; and a distal end, wherein the distal end is longitudinally opposing the inserter end; and (b) a plug ejector, wherein the plug injector comprises: a slider; and a rod coupled to a first end of the slider, wherein the plug ejector is configured to be moveable between a first position adjacent an opening in the inserter end and a second position that is further from the opening. The plug is mounted within the body and abuts first end of the rod adjacent the opening in the inserter end.

A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.

Compositions, methods, and kits for treating dry eye and related diseases are provided. In one aspect, the present disclosure relates to administering thermoresponsive polymeric compositions to the tear duct of the subject. Administering a thermoresponsive polymeric composition to the tear duct of the subject may be useful in treating dry eye and related conditions.

Prosthetic devices described herein include a body comprising a first end portion and a second end portion. The body defines a longitudinal lumen extending between the first and second end portions. In some embodiments, one or more anchor members are movably coupled to the body. Each anchor member can be selectively reconfigurable between a radially retracted position and a deployed position in which tip end portions of the one or more anchor members extend radially outward from an outer surface of the body. In some embodiments, a one-way valve is located within, and/or is otherwise in fluid communication with, the longitudinal lumen.

A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.